Literature DB >> 19648025

Pharmacokinetic of ALA and h-ALA induced porphyrins in the models Mycobacterium phlei and Mycobacterium smegmatis.

R Bruce-Micah1, D Hüttenberger, L Freitag, J Cullum, H-J Foth.   

Abstract

Photodynamic inactivation (PDI) of bacterial strains presents an attractive potential alternative to antibiotic therapies. Success is dependent on the effective accumulation in bacterial cells of photochemical substances called photosensitizers, which are usually porphyrins. It is also important to know the distribution of the photosensitizer in bacteria at the microscopic level. The present results examine the accumulation of photosensitizers by Mycobacterium phlei and Mycobacterium smegmatis, which serve as models for the important pathogens Mycobacterium tuberculosis, Mycobacterium leprae and Mycobacterium bovis. The kinetics of porphyrin synthesis after treatment with the precursors ALA and h-ALA were studied. The goal was to describe the biosynthesis and the pharmacokinetics of sensitizers in both bacterial strains using fluorescence microscopy and spectroscopy. We could show that both Mycobacterium strains enrich porphyrins after ALA and h-ALA administration detected by fluorescence peaks at about 620nm. By HPLC analyses the major porphyrin could be identified as coproporphyrin. In the future we will apply the new knowledge in in vitro and in vivo experiments to strains of M. tuberculosis, M. leprae and M. bovis and examine cell destruction by PDI.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19648025     DOI: 10.1016/j.jphotobiol.2009.07.004

Source DB:  PubMed          Journal:  J Photochem Photobiol B        ISSN: 1011-1344            Impact factor:   6.252


  2 in total

1.  [Photodynamic therapy for infectious keratitis].

Authors:  N Szentmáry; S Goebels; M Bischoff; B Seitz
Journal:  Ophthalmologe       Date:  2012-02       Impact factor: 1.059

Review 2.  Photoinactivation of mycobacteria to combat infection diseases: current state and perspectives.

Authors:  Margarita Shleeva; Alexander Savitsky; Arseny Kaprelyants
Journal:  Appl Microbiol Biotechnol       Date:  2021-05-17       Impact factor: 4.813

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.